A vaccine given during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a decrease of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and passing protection through the placenta. A major new study examining nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the timeframe when infants are most vulnerable to the virus. RSV affects roughly 50 per cent of newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the immunisation safeguards vulnerable infants
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects approximately half of all newborns during their first few months of life. The virus can vary from causing mild cold-like symptoms to triggering severe chest infections that leave babies struggling to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of infants dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening for good reason.”
The pregnancy vaccine works by activating the mother’s body’s defences to produce defence proteins, which are then transferred to the foetus through the placenta. This maternal immunity provides newborns with immediate protection from the moment of birth, exactly when they are most vulnerable to RSV. The latest research shows that protection reaches approximately 85% when the vaccine is given four weeks or more before delivery. Even briefer gaps between vaccination and birth can still deliver meaningful protection, with evidence suggesting that a fortnight’s interval is adequate to shield babies delivered prematurely. Dr Watson advises pregnant women to have the vaccine at the recommended time, whilst observing that protection remains possible even if given later in the third trimester.
- Nearly 85 per cent coverage when vaccinated four weeks before birth
- Antibodies from the mother passed through placenta protect newborns from day one
- Protection possible with 2-week gap before early delivery
- Vaccination during third trimester still provides meaningful infant protection
Persuasive evidence from recent research
The efficacy of the pregnancy RSV vaccine has been demonstrated through a comprehensive study carried out throughout England, examining data from close to 300,000 babies born between September 2024 and March 2025. This represents approximately 90 per cent of all births during that half-year window, providing robust and representative evidence of the vaccine’s real-world impact. The study’s results have been supported by the UK Health Security Agency as showing strong protection for newborns during their earliest and most vulnerable period. The scale of this research offers healthcare professionals and expectant parents with confidence in the vaccine’s established performance across varied populations and settings.
The results paint a compelling picture of the vaccine’s ability to protect. More than 4,500 babies were treated in hospital with RSV throughout the study period, with the overwhelming majority being infants whose mothers had not received the vaccination. This clear distinction underscores the vaccine’s vital importance in preventing serious illness in newborns. The decrease in hospital admissions surpassing 80 per cent represents a significant public health achievement, potentially preventing thousands of infants from experiencing the alarming and potentially severe symptoms connected with severe RSV infection. These findings strengthen the importance of the vaccination programme launched in the UK in 2024.
Research approach and coverage
The research reviewed birth and hospital admission records from England over a six-month timeframe, capturing data on approximately 90% of all births during this timeframe. By examining around 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to identify clear comparisons of RSV infection rates and hospitalisations. The large sample size and thorough nature of the data gathering ensured that findings were statistically robust and indicative of the general population, rather than individual cases or small subgroups.
The study specifically monitored hospital admissions for RSV among infants born to mothers who had received the vaccine at differing periods before delivery. This allowed researchers to establish the minimum time required between vaccination and birth for best possible protection, as well as to determine whether protection continued to be effective with shorter intervals. The methodology assessed actual clinical results rather than experimental conditions, providing practical evidence of how the vaccine performs when given across varied healthcare environments and patient circumstances throughout pregnancy’s final trimester.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Comprehending RSV and the threats
Respiratory syncytial virus, typically known as RSV, is one of the leading causes of hospital admission in infants under one year of age across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their early months of life, with severity changing substantially from mild cold-like symptoms to serious, potentially fatal chest infections. Over 20,000 infants require intensive hospital care for RSV annually in the UK alone, placing considerable pressure on paediatric wards and neonatal units during busier periods.
The infection triggers inflammation deep within the lungs and airways, making it extremely challenging for infected babies to feed and breathe properly. Parents often witness their babies visibly struggling, their chests rising whilst they attempt to draw sufficient oxygen into their weakened respiratory system. Whilst most infants get better with clinical support, a small but significant number die from respiratory syncytial virus complications each year, making immunisation programmes a critical public health objective for safeguarding the youngest and most vulnerable individuals in the population.
- RSV causes inflammation in lungs, causing serious respiratory problems in babies
- Approximately half of newborns acquire the virus in their first few months of life
- Symptoms vary between minor cold-like symptoms to life-threatening chest infections requiring hospitalisation
- Over 20,000 UK babies need serious hospital treatment for RSV annually
- Small numbers of infants succumb to RSV complications each year in the UK
Take-up rates and specialist advice
Since the RSV vaccine programme began in 2024, health officials have highlighted the importance of pregnant women receiving their jab at the optimal time for greatest protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has emphasised that the timing is essential for ensuring newborns receive the maximum immunity from birth. Whilst the study demonstrates that vaccination at least four weeks before delivery offers approximately 85% protection, experts advise women to get their vaccine as soon as feasible from 28 weeks of pregnancy forward to enhance the antibodies passed to their babies through the placenta.
The messaging from health authorities stays clear: pregnant women should prioritise vaccination during their third trimester, even if circumstances mean they cannot receive the jab at the optimal time. Dr Watson has reassured expectant mothers that protection remains still achievable with shorter intervals between immunisation and delivery, including even a two-week gap for those giving birth ahead of schedule. This adaptable strategy acknowledges the realities of pregnancy and childbirth whilst ensuring strong safeguarding for vulnerable newborns during their earliest and most vulnerable period when RSV poses the greatest risk of serious illness.
Regional variations in vaccine uptake
Whilst the RSV vaccine programme has been rolled out across England, uptake rates and implementation timelines have varied across different regions and NHS trusts. Certain regions have achieved higher vaccination coverage among qualifying expectant mothers, whilst others continue working to increase awareness and access to the jab. These geographical variations reflect variations in healthcare infrastructure, communication strategies, and local engagement efforts, though the overall statistics shows robust and reliable protection irrespective of geographical location.
- NHS trusts deploying varied communication campaigns to connect with expectant mothers
- Regional disparities in immunisation take-up across England necessitate strategic intervention
- Local healthcare systems adapting programmes to meet local requirements and situations
Real-world impact and parent viewpoints
The vaccine’s impressive effectiveness provides real advantages for families across the United Kingdom. With over 20,000 babies admitted to hospital annually due to RSV prior to the rollout of this protective measure, the 80% drop in admissions equates to thousands of infants protected against serious illness. Parents no more face the upsetting situation of seeing their babies struggle for breath or difficulty feeding, symptoms that characterise serious RSV disease. The vaccine has fundamentally shifted the picture of neonatal breathing health, giving expectant mothers a proactive tool to shield their most vulnerable children during those vital initial period.
For families like that of Malachi, whose serious RSV infection resulted in devastating brain damage, the vaccine’s introduction carries significant emotional significance. His mother’s promotion of the jab underscores the profound consequences that preventable illness can inflict on young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story resonates powerfully with parents now given protection. The knowledge that such serious complications—hospital admission, oxygen dependency, neurological damage—are now largely preventable has given considerable reassurance to expectant mothers during their late pregnancy, changing what was once an inevitable seasonal threat into a manageable health risk.